Anti-C5 [Eculizumab]

Description:

Recombinant monoclonal antibody to C5. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody Eculizumab.

Clone Name:

Eculizumab

Published Application(s):

Block, ELISA, EM

Published Species Reactivity:

Human

Products based on this clone:

{{heading}}

Please Select

Ab00296-1.1 Anti-C5 [Eculizumab]
Human
Mouse IgG1
Purified
In Stock

Ab00296-10.6 Anti-C5 [Eculizumab]
Human
Human Fab fragment
His-Tagged
Purified
In Stock

Ab00296-23.0 Anti-C5 [Eculizumab]
Human
Rabbit IgG
Purified
In Stock

Ab00296-25.0 Anti-C5 [Eculizumab]
Human
Human IgG2/4
Purified
In Stock

UniProt Accession Number of Target Protein: P01031

Alternative Name(s) of Target: Complement Component 5; CPAMD4; Complement protein C5; h5G1.1
Immunogen: C5 is activated by C5 converatse into C5a, an anaphylatoxin, and C5b a component of the membrane attack complex.

Specificity: Binds human C5 centred in the MG7 domain, at an epitope spanning Lys-879 to Arg-885 (Jore et al. 2016) Polymorphisms at Arg-885 correlate with drug resistance. Eculizumab demonstrates no appreciable species cross-reactivity. It is highly species specific. with no appreciable activity against chimpanzee, baboon, rhesus or cynomologous monkey, pig, rabbit, guinea pig, or rat complement

Application Notes: This antibody inhibits activation of C5. The human Fab version (Ab00296-10.6) of this antibody was used by Jore et al. (2016, PMID: 27018802) to determine the binding site of this antibody to C5.

Antibody first published in: Rother et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. PMID:17989688
Note on publication: Describes development and characterisation of Eculizumab.